Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tinidazole -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tinidazole -

Israel - anglès - Ministry of Health

unipharm ltd, israel - hydrochlorothiazide; losartan potassium - tablets - losartan potassium 50 mg; hydrochlorothiazide 12.5 mg - lotan plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Israel - anglès - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 100 mg - losartan - hypertension: lotan 100 is indicated for the treatment of hypertension. heart failure:lotan 100 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 100 is not recommended. renal protection in type-2 diabetic patients with proteinuria: lotan 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of lotan 100 on the

Israel - anglès - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 12.5 mg - losartan - heart failure: lotan 12.5 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 12.5 mg is not recommended

Israel - anglès - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - hypertension: lotan 50 mg is indicated for the treatment of hypertensionheart failure: lotan 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to lotan 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: lotan 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventri

Israel - anglès - Ministry of Health

unipharm ltd, israel - hydrochlorothiazide; losartan potassium - tablets - losartan potassium 50 mg; hydrochlorothiazide 12.5 mg - lotan plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

santen pharma malaysia sdn. bhd. - tafluprost -